FCH
TARO

Freestone Capital Holdings’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Freestone Capital Holdings’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,633
Closed -$120K – 1190
2020
Q4 		$120K Sell
1,633
-618
-27% -$39.7K 0.01% 406
2020
Q3 		$123K Buy
+2,251
New +$140K 0.01% 375
2020
Q2 		– Sell
-3,931
Closed -$241K – 396
2020
Q1 		$241K Sell
3,931
-10,384
-73% -$769K 0.01% 329
2019
Q4 		$1.26M Sell
14,315
-5,556
-28% -$469K 0.03% 234
2019
Q3 		$1.5M Sell
19,871
-5,250
-21% -$426K 0.04% 206
2019
Q2 		$2.15M Sell
25,121
-104,636
-81% -$10.3M 0.05% 155
2019
Q1 		$14M Buy
129,757
+33,130
+34% +$3.3M 0.83% 28
2018
Q4 		$8.18M Sell
96,627
-44,092
-31% -$4.25M 0.55% 48
2018
Q3 		$13.8M Sell
140,719
-4,244
-3% -$459K 0.09% 39
2018
Q2 		$16.8M Sell
144,963
-21,785
-13% -$2.39M 0.11% 37
2018
Q1 		$16.5M Buy
166,748
+21,392
+15% +$2.17M 0.96% 35
2017
Q4 		$15.2M Sell
145,356
-2,125
-1% -$233K 1.05% 29
2017
Q3 		$16.6M Buy
147,481
+4,731
+3% +$515K 1.18% 22
2017
Q2 		$16M Buy
142,750
+441
+0.3% +$49.8K 1.25% 24
2017
Q1 		$16.6M Buy
142,309
+57,409
+68% +$6.35M 1.28% 28
2016
Q4 		$8.94M Sell
84,900
-4,105
-5% -$430K 0.77% 32
2016
Q3 		$9.84M Sell
89,005
-31,162
-26% -$4.13M 0.9% 30
2016
Q2 		$17.5M Buy
120,167
+7,257
+6% +$1.03M 1.71% 21
2016
Q1 		$16.2M Sell
112,910
-5,909
-5% -$839K 1.7% 25
2015
Q4 		$18.4M Buy
118,819
+111,181
+1,456% +$16.2M 1.9% 14
2015
Q3 		$1.09M Buy
+7,638
New +$1.07M 0.12% 140

Other funds holding TARO

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

Freestone Capital Holdings's TARO Position: Q1 2021 in Review

Freestone Capital Holdings sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q1 2021, closing a stake of 1,633 shares — an estimated $120K sold.

Freestone Capital Holdings first reported a position in TARO in Q3 2015 and held it in 21 quarters. The position peaked at $18.4M in Q4 2015. 80 funds tracked by Wall St. Rank hold TARO as of Q1 2021.

  • Freestone Capital Holdings reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q1 2021 after selling out during the quarter.
  • Freestone Capital Holdings sold 1,633 Taro Pharmaceutical Industries Ltd. shares in Q1 2021, an estimated $120K.
  • Freestone Capital Holdings first reported a position in Taro Pharmaceutical Industries Ltd. in Q3 2015 and held it in 21 quarters.
  • Freestone Capital Holdings's Taro Pharmaceutical Industries Ltd. position peaked at $18.4M in Q4 2015.
  • 80 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q1 2021.

Based on Freestone Capital Holdings's 13F filing for Q1 2021, filed 17 May 2021.